NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $232,000 | +20.2% | 10,731 | +1.2% | 0.00% | +100.0% |
| Q3 2019 | $193,000 | -54.0% | 10,599 | -10.3% | 0.00% | -66.7% |
| Q2 2019 | $420,000 | +53.3% | 11,810 | +45.5% | 0.00% | +50.0% |
| Q1 2019 | $274,000 | +25.7% | 8,116 | +22.3% | 0.00% | 0.0% |
| Q4 2018 | $218,000 | -34.7% | 6,638 | +21.4% | 0.00% | -33.3% |
| Q3 2018 | $334,000 | +345.3% | 5,470 | +258.5% | 0.00% | +200.0% |
| Q2 2018 | $75,000 | -47.9% | 1,526 | +13.0% | 0.00% | -50.0% |
| Q1 2018 | $144,000 | +48.5% | 1,350 | -17.1% | 0.00% | +100.0% |
| Q4 2017 | $97,000 | +155.3% | 1,628 | +4.8% | 0.00% | 0.0% |
| Q3 2017 | $38,000 | +22.6% | 1,553 | +0.4% | 0.00% | 0.0% |
| Q2 2017 | $31,000 | 0.0% | 1,547 | +18.8% | 0.00% | 0.0% |
| Q1 2017 | $31,000 | +121.4% | 1,302 | +9.3% | 0.00% | – |
| Q4 2016 | $14,000 | -48.1% | 1,191 | -22.7% | 0.00% | -100.0% |
| Q3 2016 | $27,000 | +42.1% | 1,541 | +6.9% | 0.00% | – |
| Q2 2016 | $19,000 | – | 1,441 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |